Home / Company / Business Development

DanioLabs generates revenues from the application of our technologies by undertaking discovery processes:

• For others – Revenue Generating Collaborations;
• With others – Risk Sharing Collaborations;
• For ourselves – Licensing.

Revenue Generating Collaborations:
Under these collaborations, DanioLabs undertakes work on behalf of our partners for an agreed fee. An example would be the screening of novel compounds provided by a collaborator in one of our established assays. The collaborator generally keeps any intellectual property that is generated from th collaboration.

Risk-Sharing Collaborations:
This differs from the revenue generating collaborations, in that DanioLabs undertakes work for either a reduced fee, or some share of future revenues - normally through intellectual property creation, which is either owned by DanioLabs and is committed to a shared project, or is shared with the other partner from the outset of the programme.

Licensing:
With a primary focus (although not exclusively) on neurological and ophthalmic disease, DanioLabs has on-going drug discovery and development programmes. These programmes and products will be licensed out to partners with an active franchise in the areas at a suitable clinical proof of principal stage – likely to be Phase II. In return DanioLabs expect to receive access, milestone and royalty payments.